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ABSTRACT
We report two Malaysian siblings with neonatal 
intrahepatic cholestasis caused by citrin deficiency 
(NICCD). The younger sibling, a six-month-old 
Chinese girl, presented with prolonged neonatal 
jaundice, and was investigated for biliary atresia. 
Urine metabolic screen showed the presence of 
urinary-reducing sugars, and she was treated with 
a lactose-free formula. NICCD was suspected 
based on the clinical history, examination and 
the presence of urinary citrulline. Mutation study 
of the SLC25A13 gene showed the compound 
heterozygotes, 851del4 and IVS16ins3kb, which 
confirmed the diagnosis of NICCD in the patient 
and her three-year-old female sibling, who also 
had unexplained neonatal cholestasis. Long-
term dietary advice, medical surveillance and 
genetic counselling were provided to the family. 
The diagnosis of NICCD should be considered 
in infants with unexplained prolonged jaundice. 
DNA-based genetic testing of the SLC25A13 
gene may be performed to confirm the diagnosis 
retrospectively. An awareness of this condition 
may help in early diagnosis using appropriate 
metabolic and biochemical investigations, thus 
avoiding invasive investigations in infants with 
neonatal cholestasis caused by NICCD. 
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INTRODUCTION
Citrin is a mitochondrial inner membrane aspartate-
glutamate carrier that functions as part of the malate-
aspartate shuttle, transferring cytosolic-reduced 
nicotinamide adenine dinucleotide into the mitochondria. 
It plays a role in the synthesis of urea, protein and 
nucleotide by supplying mitochondrial aspartate to the 
cytosol in the liver.(1) There are two disease entities 
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attributed to the deficiency of citrin: neonatal intrahepatic 
cholestasis caused by citrin deficiency (NICCD; 
OMIM#605814) and adult-onset Type II citrullinaemia 
(CTLN2; OMIM#603471).(2)  Infants with NICCD often 
present with transient intrahepatic cholestasis with mild 
liver dysfunction, hepatomegaly, transient multiple 
aminoacidaemia (citrulline, methionine, tyrosine) and 
hypoglycaemia. To the best of our knowledge, these two 
conditions and their outcomes have not been published 
in the English medical literature from Southeast Asia.
CASE REPORT
A six-month-old Malaysian Chinese baby girl of non-
consanguineous parents was referred to the University 
of Malaya Specialist Centre at six weeks of life for 
investigation of prolonged neonatal jaundice. The 
antenatal period was uneventful, and she was delivered 
at term with a birth weight of 2.75 kg. She was initially 
breastfed but later received additional formula feeds. 
Her stools were pale yellow in colour. Although she was 
thriving well, she was noted to be jaundiced from the 
first month of life and was investigated for prolonged 
jaundice. On review of the family history, it was found 
that the patient had an elder sister, aged three years old, 
who also had jaundice from one to three months of age. 
Her urinary-reducing sugar was positive. The sister was 
initially treated in another hospital. Her jaundice had 
disappeared after lactose-free formula was started so no 
other investigation was performed.
 The physical examination confirmed the presence 
of jaundice in the patient. She was thriving well 
and had no dysmorphic features. The abdominal 
examination revealed a soft palpable liver 2 cm below 
the right subcostal margin. The rest of the findings 
were non-contributory. The investigations showed 
hyperbilirubinaemia 210 (control range 3–17) umol/L 
with conjugated fraction 126 (control range 0–3) umol/
L, serum alkaline phosphatase  9,813 (control range 50–
136) IU/L, serum alanine aminotransferase 47 (control 
range 30–65) IU/L, serum aspartate aminotransferase 
168 (control range 15–37) IU/L and gamma glutamyl 
transferase 285 (control range 5–55) IU/L. The full blood 
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count, hypothyroid screen and glucose-6-phosphate 
dehydrogenase screen were normal. The alpha-
1antitrypsin and serum TORCH screens were normal. 
Ultrasonography of the liver and abdomen was normal, 
but the isotope study with hepatobiliary iminodiacetic 
acid scan did not show any excretion. An on-table 
cholangiogram, however, showed good excretion into 
the small intestine, excluding the possibility of biliary 
atresia. The liver biopsy showed marked cholestasis 
with ballooning degeneration and fibrosis of the portal 
tracts. No inflammatory cell was noted.
 The urine metabolic screen showed the presence 
of urinary-reducing sugars (positive) and tyrosine 
(positive) on two occasions. In view of the suspicion of 
galactosaemia, she was empirically started on a lactose-
free formula, and breastfeeding was stopped. The 
urinary-reducing sugars subsequently became negative. 
The galactose-1-phosphate uridyl transferase assay and 
the urinary succinylacetone level were normal, while 
the urine organic acid showed a marked increase in 4-
hydroxyphenylacetic acid, 4-hydroxyphenyllactic acid, 
4-hydroxyphenylpyruvic acid and n-acetyl tyrosine, 
which was consistent with liver impairment. The urine 
amino acid showed a marked elevation of urine citrulline 
and a slight increase in tyrosine, histidine and alanine, 
with an absence of succinylacetone and argininosuccinic 
acid, suggesting NICCD. Plasma amino acid tests were 
not done at that time. Mutation analysis of the SLC25A13 
gene was performed at the Department of Molecular 
Metabolism and Biochemical Genetics, Kagoshima 
University Graduate School of Medical and Dental 
Sciences, Kagoshima, Japan. The results showed that the 
patient was a compound heterozygote for two different 
mutations: a known 851del4(3) and a novel IVS16ins3kb 
that was reported recently.(4) 
 On review at five months of age, the patient 
had recovered well. The liver function test, serum 
ammonium, urine and plasma amino acid assays were 
normal. The caregivers were counselled regarding the 
condition. Appropriate dietary advice was provided to 
the parents, who were told to ensure that the patient 
maintained a high-protein and low-carbohydrate diet, 
and avoided paracetamol and other antiinflammatory 
medications. The patient was well at one year of life. 
After the diagnosis of NICCD was made in the patient, 
the older sibling was tested and found to have the 
identical compound heterozygous mutations, 851del4 
and IVS16ins3kb. Following this molecular diagnosis, 
the parents were counselled that both their daughters 
have NICCD. The older sister has remained well and has 
no specific food preference.
DISCUSSION
While NICCD during infancy is not considered a life-
threatening disease, it is vital to note that three affected 
individuals had undergone liver transplantation.(5) 
The clinical features may include intrahepatic 
cholestasis, diffuse fatty liver with parenchymal 
cellular infiltration associated with hepatic fibrosis 
and variable liver dysfunctions, such as coagulopathy 
and hypoalbuminaemia. This may lead to extensive 
investigations in the affected infant to exclude 
biliary atresia. Other clinical features include ketotic 
hypoglycaemia, hepatomegaly and haemolytic anaemia 
in childhood. As awareness of NICCD is generally 
low, these patients may be empirically treated for 
galactosaemia with lactose-free formula. After weaning, 
the patient with NICCD may show an aversion to 
carbohydrate-rich foods and a fondness for protein-rich 
foods. 
 Unfortunately, some individuals with NICCD 
may develop CTLN2 with neuropsychiatric features 
during early adulthood.(2) CTLN2 is a severe condition 
characterised by recurrent episodes of hyperammonaemia 
and neuropsychiatric symptoms, such as nocturnal 
delirium, irritability, delusions, disorientation, changes 
in sensorium, convulsions and coma. Death may result 
from cerebral oedema. The onset is sudden, and the 
precipitating factors may include alcohol ingestion, 
medications or surgery. The liver may show fatty 
infiltration and mild fibrosis, with minimal liver 
dysfunction. Although the prognosis of CTLN2 is 
guarded, it is amenable to liver transplantation.(6)
 The differential diagnoses may include 
citrullinaemia Type 1 (CTLN1), argininosuccinic 
aciduria and pyruvate carboxylase deficiency in patients 
presenting with increased urinary or  plasma citrulline. 
Hyperammonaemia may lead one to suspect urea 
cycle defect and organic acidemias. The neonate with 
cholestasis may be investigated for galactosaemia, 
biliary atresia, Byler disease and other forms of 
hereditary hyperbilirubinaemia. The diagnosis of 
NICCD is made based on the history and the above 
mentioned physical examination findings, and supported 
by transient aminoacidaemia (citrulline, methionine, 
tyrosine), transient galactosuria, an increased alpha 
foetoprotein concentration and the presence of mild liver 
dysfunction. The symptoms and abnormal biochemical 
findings disappear by one year of age. Due to the 
transient nature of the biochemical abnormalities in 
NICCD, genetic testing is useful when the patient is 
seen after the first year of life, or when the parents are 
considering prenatal diagnosis. In addition, the parents of 
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patients with NICCD confirmed by genetic testing may 
receive early counselling on the risk of CTLN2 for their 
children, which will change their long-term management 
and health surveillance program.  For example, as the 
outcome of NICCD patients is not always benign, the 
confirmation of their status as NICCD by genetic testing 
may mean a life-time of dietary modifications and early 
preparation for liver transplantation, if they develop 
recurring neuropsychiatric symptoms.(4)  A patient with 
“idiopathic” neonatal cholestasis may not be subjected 
to similar restrictions or concerns. Therefore, continuing 
research and follow-up of these families are important 
for future reference.
 The frequency carriers for the SLC25A13 mutation 
is one in 65 and one in 48 in the Japanese and Southern 
Chinese populations, respectively.(4,7) Recently, NICCD 
was reported in  patients from Israel,(4,8)  the United States 
of America,(9) the United Kingdom(4,10) and the Czech 
Republic.(4) Increasingly, this condition is being detected 
through expanded newborn screening programmes.(11,12) 
There is a need for greater awareness of this disease 
entity in this part of Southeast Asia. This is to avoid 
unnecessary and potentially hazardous investigations 
in infants. As such, it would be reasonable to consider 
this diagnosis in the workup for patients with neonatal 
cholestasis. This condition is also amenable to dietary 
management, which consists of a high-protein and low-
carbohydrate diet, and avoidance of risk factors, such as 
alcohol and certain drugs. As this an autosomal recessive 
condition, genetic counselling should be provided to 
the affected family. Mutation study of the SLC25A13 
gene may be used when the diagnosis is uncertain, or 
when prenatal diagnosis is being considered. In our 
case, the molecular diagnostic approach had confirmed 
the diagnosis of NICCD in both patients. Long-term 
health and medical surveillance has been provided 
for the family. Therefore, the diagnosis of NICCD in 
infants with unexplained prolonged jaundice should be 
considered, with a DNA-based genetic testing of the 
SLC25A13 gene performed to confirm the diagnosis. 
 The detailed methods for the identification and 
diagnosis of the novel mutation, IVS16ins3kb, which 
was first found and characterised in a Japanese CTLN2 
patient, have been described in the literature.(4) However, 
the clinical and biochemical data have previously 
been reported mainly in Japanese,(13,14) Korean(15,16) 
and Chinese(4) NICCD patients with the IVS16ins3kb 
mutation, and  it is well known that many patients 
and carriers of the mutation 851del4 are found widely 
in East Asia.(4,7) Therefore, the presence of both these 
mutations in Malaysian Chinese patients, as reported in 
this case, suggests that the IVS16ins3kb mutation, like 
the 851de14 mutation, may also be widely distributed in 
East Asia.(3)
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